Literature DB >> 27115142

Sphingosine-1-Phosphate Signaling in Endothelial Disorders.

Teresa Sanchez1.   

Abstract

Numerous preclinical studies indicate that sustained endothelial activation significantly contributes to tissue edema, perpetuates the inflammatory response, and exacerbates tissue injury ultimately resulting in organ failure. However, no specific therapies aimed at restoring endothelial function are available as yet. Sphingosine-1-phosphate (S1P) is emerging as a potent modulator of endothelial function and endothelial responses to injury. Recent studies indicate that S1PR are attractive targets to treat not only disorders of the arterial endothelium but also microvascular dysfunction caused by ischemic or inflammatory injury. In this article, we will review the current knowledge of the role of S1P and its receptors in endothelial function in health and disease, and we will discuss the therapeutic potential of targeting S1PR not only for disorders of the arterial endothelium but also the microvasculature. The therapeutic targeting of S1PR in the endothelium could help to bridge the gap between biomedical research in vascular biology and clinical practice.

Entities:  

Keywords:  Atherosclerosis; Blood–brain barrier; Brain edema; Coronary artery disease; Hemorrhagic transformation; Immunosuppression; Malignant middle cerebral artery syndrome; Microcirculation; Microvascular dysfunction; Neurovascular injury; Non-reflow phenomenon; Stroke reperfusion therapies; Translational research; Vasogenic edema

Mesh:

Substances:

Year:  2016        PMID: 27115142     DOI: 10.1007/s11883-016-0586-1

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  99 in total

1.  Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists.

Authors:  Suzanne Mandala; Richard Hajdu; James Bergstrom; Elizabeth Quackenbush; Jenny Xie; James Milligan; Rosemary Thornton; Gan-Ju Shei; Deborah Card; CarolAnn Keohane; Mark Rosenbach; Jeffrey Hale; Christopher L Lynch; Kathleen Rupprecht; William Parsons; Hugh Rosen
Journal:  Science       Date:  2002-03-28       Impact factor: 47.728

2.  Fingolimod provides long-term protection in rodent models of cerebral ischemia.

Authors:  Ying Wei; Muge Yemisci; Hyung-Hwan Kim; Lai Ming Yung; Hwa Kyoung Shin; Seo-Kyoung Hwang; Shuzhen Guo; Tao Qin; Nafiseh Alsharif; Volker Brinkmann; James K Liao; Eng H Lo; Christian Waeber
Journal:  Ann Neurol       Date:  2010-11-12       Impact factor: 10.422

3.  Flow-regulated endothelial S1P receptor-1 signaling sustains vascular development.

Authors:  Bongnam Jung; Hideru Obinata; Sylvain Galvani; Karen Mendelson; Bi-sen Ding; Athanasia Skoura; Bernd Kinzel; Volker Brinkmann; Shahin Rafii; Todd Evans; Timothy Hla
Journal:  Dev Cell       Date:  2012-09-11       Impact factor: 12.270

4.  Sphingosine-1 phosphate prevents monocyte/endothelial interactions in type 1 diabetic NOD mice through activation of the S1P1 receptor.

Authors:  Angela M Whetzel; David T Bolick; Suseela Srinivasan; Timothy L Macdonald; Margaret A Morris; Klaus Ley; Catherine C Hedrick
Journal:  Circ Res       Date:  2006-09-07       Impact factor: 17.367

5.  The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice.

Authors:  Petra Keul; Markus Tölle; Susann Lucke; Karin von Wnuck Lipinski; Gerd Heusch; Mirjam Schuchardt; Markus van der Giet; Bodo Levkau
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-12-07       Impact factor: 8.311

6.  Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation.

Authors:  Clemens Feistritzer; Matthias Riewald
Journal:  Blood       Date:  2004-12-30       Impact factor: 22.113

7.  Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate.

Authors:  Douglas H Deutschman; Jeffrey S Carstens; Robert L Klepper; Wyatt S Smith; M Trevor Page; Thomas R Young; Lisa A Gleason; Nobuko Nakajima; Roger A Sabbadini
Journal:  Am Heart J       Date:  2003-07       Impact factor: 4.749

8.  High density lipoprotein-associated sphingosine 1-phosphate promotes endothelial barrier function.

Authors:  Kelley M Argraves; Patrick J Gazzolo; Eric M Groh; Brent A Wilkerson; Bryan S Matsuura; Waleed O Twal; Samar M Hammad; W Scott Argraves
Journal:  J Biol Chem       Date:  2008-07-07       Impact factor: 5.157

9.  Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate.

Authors:  Rajita Pappu; Susan R Schwab; Ivo Cornelissen; João P Pereira; Jean B Regard; Ying Xu; Eric Camerer; Yao-Wu Zheng; Yong Huang; Jason G Cyster; Shaun R Coughlin
Journal:  Science       Date:  2007-03-15       Impact factor: 47.728

10.  The immunomodulatory sphingosine 1-phosphate analog FTY720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia.

Authors:  Bozena Czech; Waltraud Pfeilschifter; Niloufar Mazaheri-Omrani; Marc André Strobel; Timo Kahles; Tobias Neumann-Haefelin; Abdelhaq Rami; Andrea Huwiler; Josef Pfeilschifter
Journal:  Biochem Biophys Res Commun       Date:  2009-08-29       Impact factor: 3.575

View more
  16 in total

1.  Lmo2 (LIM-Domain-Only 2) Modulates Sphk1 (Sphingosine Kinase) and Promotes Endothelial Cell Migration.

Authors:  Gianfranco Matrone; Shu Meng; Qilin Gu; Jie Lv; Longhou Fang; Kaifu Chen; John P Cooke
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-08-03       Impact factor: 8.311

2.  Size-selective opening of the blood-brain barrier by targeting endothelial sphingosine 1-phosphate receptor 1.

Authors:  Keisuke Yanagida; Catherine H Liu; Giuseppe Faraco; Sylvain Galvani; Helen K Smith; Nathalie Burg; Josef Anrather; Teresa Sanchez; Costantino Iadecola; Timothy Hla
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-10       Impact factor: 11.205

Review 3.  Renal microvascular endothelial cell responses in sepsis-induced acute kidney injury.

Authors:  Grietje Molema; Jan G Zijlstra; Matijs van Meurs; Jan A A M Kamps
Journal:  Nat Rev Nephrol       Date:  2021-10-19       Impact factor: 28.314

Review 4.  The immunopathology of sepsis and potential therapeutic targets.

Authors:  Tom van der Poll; Frank L van de Veerdonk; Brendon P Scicluna; Mihai G Netea
Journal:  Nat Rev Immunol       Date:  2017-04-24       Impact factor: 53.106

5.  Evaluation of S1PR1, pSTAT3, S1PR2, FOXP1 Expression in Aggressive, Mature B Cell Lymphomas.

Authors:  Mustafa Al-Kawaaz; Teresa Sanchez; Michael J Kluk
Journal:  J Hematop       Date:  2019-04-27       Impact factor: 0.196

6.  Long-term consumption of an obesogenic high fat diet prior to ischemia-reperfusion mediates cardioprotection via Epac1-dependent signaling.

Authors:  F Edland; A Wergeland; R Kopperud; K S Åsrud; E A Hoivik; S L Witsø; R Æsøy; L Madsen; K Kristiansen; M Bakke; S O Døskeland; A K Jonassen
Journal:  Nutr Metab (Lond)       Date:  2016-11-28       Impact factor: 4.169

Review 7.  Endothelial glycocalyx as a critical signalling platform integrating the extracellular haemodynamic forces and chemical signalling.

Authors:  Ye Zeng
Journal:  J Cell Mol Med       Date:  2017-02-17       Impact factor: 5.310

Review 8.  Low-Density Lipoprotein Receptor-Related Protein-1 Signaling in Angiogenesis.

Authors:  Hua Mao; Liang Xie; Xinchun Pi
Journal:  Front Cardiovasc Med       Date:  2017-05-22

Review 9.  The S1P-S1PR Axis in Neurological Disorders-Insights into Current and Future Therapeutic Perspectives.

Authors:  Alexandra Lucaciu; Robert Brunkhorst; Josef M Pfeilschifter; Waltraud Pfeilschifter; Julien Subburayalu
Journal:  Cells       Date:  2020-06-22       Impact factor: 6.600

Review 10.  Sphingosine 1-Phosphate Signaling as a Target in Hepatic Fibrosis Therapy.

Authors:  Bárbara González-Fernández; Diana I Sánchez; Javier González-Gallego; María J Tuñón
Journal:  Front Pharmacol       Date:  2017-08-25       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.